Glycopyrronium Cantabria

Glycopyrronium Cantabria is a cutaneous formulation containing the anticholinergic agent glycopyrronium. The product is marketed in the European Union and is classified as a muscarinic antagonist (ATC code D11AH02). It is intended for topical application to reduce excessive sweating. While specific strength and dosage form are not disclosed, the medication works by competitively blocking muscarinic acetylcholine receptors in sweat glands in the affected areas for patients with hyperhidrosis.

Glycopyrronium Cantabria is primarily indicated for the management of primary axillary hyperhidrosis, a condition characterized by excessive under‑arm sweating.

- Reduces sweat production in the under‑arm region when applied as directed. - May be used as an alternative to oral anticholinergics for localized treatment. - Can be considered for patients who have not responded adequately to topical aluminum‑based antiperspirants. - Suitable for adults and adolescents when prescribed by a healthcare professional. - May improve quality‑of‑life measures related to social and occupational activities.

The safety profile of Glycopyrronium Cantabria includes both frequently observed and less common adverse reactions.

Common: - Transient skin irritation or erythema at the application site. - Mild pruritus or itching where the product is applied. - Dryness of the treated skin. - Temporary reduction in local sweating that may be perceived as excessive dryness.

Serious: - Allergic contact dermatitis presenting with swelling, blistering, or severe rash. - Systemic anticholinergic effects such as dry mouth, blurred vision, or urinary retention, especially if applied over large areas. - Unexpected tachycardia or palpitations. - Severe skin necrosis (rare).

Before initiating therapy with Glycopyrronium Cantabria, certain precautions and warnings should be considered.

- Avoid application to broken, inflamed, or infected skin. - Do not use on areas other than the axillae unless directed by a clinician. - Patients with narrow‑angle glaucoma or urinary retention should discuss use with their physician. - Pregnant or breastfeeding individuals should be evaluated for potential risks, as safety data are limited. - Concomitant use with other topical anticholinergics may increase local adverse effects. - Keep the product out of reach of children; accidental ingestion can cause systemic anticholinergic toxicity. - Discontinue use and seek medical advice if severe skin reactions develop.

Glycopyrronium Cantabria may interact with other medications or substances that influence anticholinergic activity.

Avoid: - Concurrent use of systemic anticholinergic drugs (e.g., atropine, scopolamine) that could amplify anticholinergic side effects. - Application together with other topical agents containing anticholinergic compounds.

Use with caution: - Beta‑blockers or antihypertensive agents if systemic absorption leads to cardiovascular effects. - Drugs that affect sweating regulation, such as certain antidepressants or antipsychotics. - Alcohol or sedatives, which may exacerbate dry mouth or blurred vision.